Roche
FY Revenues: 58.3 billion CHF (-5%)
FY Earnings 15.1 billion CHF (+7%)
Pharmaceuticals sales were down 2% for the year. Newly launched medicines had continued sales growth (+32%), including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla, offsetting the impact of competition from biosimilars for the established medicines Herceptin, Avastin and MabThera/Rituxan, with an estimated combined CHF 5.1 billion of sales decline in the U.S, Europe and Japan. The COVID-19 pandemic had an overall negative impact on pharmaceutical sales in 2020, especially for medicines where regular visits to health practices or hospitals are needed. This was partly compensated by additional sales of Actemra/RoActemra (+32%) mostly due to treatment of patients with severe COVID-19-associated pneumonia.